Cost-effectiveness in clinical cardiology: Part 1: Coronary artery disease and congestive heart failure

Chest

Volumn 109, Issue 5, 1996, Pages 1359-1369

  Willens, Howard J ^b   Chakko, Simon ^b   Simmons, Jeffrey ^b   Kessler, Kenneth M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

acute myocardial infarction; angiotensin converting enzyme inhibitors; atrial fibrillation; congestive heart failure; coronary artery disease; cost effectiveness; myocardial revascularization

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0029919581     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.5.1359     Document Type: Article

References (60)

1. Diamond GA, Denton TA. Alternative perspectives on the biased foundations of medical technology assessment. Ann Intern Med 1993; 118:455-64
2. American Heart Association. 1994; Publication No. 44-1027 (OPA), 1-7
3. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease: I. General principles. Prog Cardiovasc Dis 1994; 37:161-84
4. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989; 262:2879-86
5. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113:147-158
6. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296:716-21
7. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85;1960-68
8. Sox HC, Blatt MA, Higgins MC, et al. Medical decision making. Stoneham, Mass: Butterworth, 1988: 1-23
9. Patterson RE, Eng C, Horowitz SF, et al. Bayesian comparison of cost-effectiveness of different clinical approaches to diagnose coronary artery disease. J Am Coll Cardiol 1984; 4:278-89
10. Stason WB, Fineberg HV. Implications of alternative strategies to diagnose coronary artery disease. Circulation 1982; 66(suppl III): III80-86
11. Doubilet P, McNeil BJ, Weinstein MC. The decision concerning coronary angiography in patients with chest pain: a cost-effectiveness analysis. Med Decis Making 1985; 5:293-309
12. Lee TH, Fukui T, Weinstein MC, et al. Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina. Med Decis Making 1988; 8:268-78
13. Warwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an aceurate and cost-efficient technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26:335-41
14. Goldman L, Weinberg M, Weisberg MC, et al. A computer derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N Engl J Med 1982; 307:588-96
15. Lee TH, Goldman L. The coronary care unit turns 25: historical trends and future directions. Ann Intern Med 1988; 108:887-94
16. Fineberg HV, Scadden D, Goldman L. Care of patients with a low probability of acute myocardial infarction: cost effectiveness of alternatives to coronary-care-unit admission. N Engl J Med 1984; 310:1301-07
17. Gaspoz J-M, Lee TH, Weinstein MC, et al. Cost-effectiveness of a new short-stay unit to 'rule out' acute myocardial infarction in low risk patients. J Am Coll Cardiol 1994; 24:1249-59
18. Gunnar RM, Bourdillon PD, Dixon DW, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990; 16:249-92
19. Laffel GL, Fineberg HV, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987; 10(suppl B):79B-90B
20. Steinberg EP, Topol EJ, Sakin JW, et al. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1988; 12:(suppl A)58A-68A
21. Midgette AS, Wong JB, Beshansky JR, et al. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994; 14:108-17
22. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost-effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7-13
23. Chapekis AT Burek K, Topol EJ. The cost-benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis. Am Heart J 1989; 118:878-82
24. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-24
25. Hennekens CH, Jonas MAS, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the United States. Arch Intern Med 1994; 154:37-9
26. Mark DB, O'Neill WW, Brodie B, et al. Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry. J Am Coll Cardiol 1995; 26:688-95
27. Gilpin EA, Koziol JA, Madsen EG, et al. Periods of differing mortality distribution during the first year after myocardial infarction. Am J Cardiol 1983; 52:240-44
28. DeBusk RF, Blomqvist CG, Kochonkos NT, et al. Identification and treatment of low-risk patients after acute myocardial infarction and coronary-artery bypass graft surgery. N Engl J Med 1986; 314:161-66
29. Dittus RS, Roberts SD, Adolph RJ. Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction: a model. J Am Coll Cardiol 1987; 10:869-78
30. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-71
31. Goldman L, Sia STB, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319:152-57
32. LeJemtel JH, Hochman JS, Sonnenblick EH. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25(suppl):47S-51S
33. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26:914-19
34. van Bergen PFMM, Jonker JJC, van Hont BA, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995; 273:925-28
35. Gazpoz J-M, Goldman P, Williams L, et al. Cost-effectiveness of aspirin in secondary prevention of coronary heart disease. Circularion 1995; 92(suppl):1-47
36. Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation after acute myocardial infarction. Am J Cardiol 1993; 72:154-61
37. Vamauskas E, European Coronary Surgery Study Group. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319:332-37
38. Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass snrgery for stable angina. N Engl J Med 1984; 311:1333-39
39. Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary bypass surgery: eight years follow-up and survival in patients with reduced ejection fraction. Circulation 1985; 72(6 pt 2):V102-09
40. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563-70
41. ACC/AHA Task Force Report. Guidelines and indications for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1991; 17:543-89
42. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982; 66(suppl III):III56-66
43. Parisi AF, Folland ED, Hartigan P, et al. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992; 326:10-6
44. BARI, CABRI, EAST GABI, RITA. Coronary angioplasty on trial [editorial]. Lancet 1990; 335:1315-16
45. Ryan TJ, Bauman WB, Kennedy JW, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993; 88:2987-3007
46. Wong JB, Sonnenberg FA, Salem DN, et al. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneons transluminal coronary angioplasty based on data in 1989. Ann Intern Med 1990; 113:852-87
47. Cohen DJ, Breall JA, Ho KKL, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model. Circulation 1994; 89:1859-74
48. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:687-91
49. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-77
50. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med 1986; 314:1547-52
51. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302
52. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrite in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10
53. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyine inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154:1143-49
54. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of varions initial monotherapies for mild to moderate hypertension. JAMA 1990; 263:407-13
55. Kleber FX. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases. Am J Hypertens 1994; 7: 112S-16S
56. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest 1992; 102:538S-49S
57. Goodnight SH. Pathogenesis and therapy of thrombosis in patients with congestive heart failure. In: Hosenpud JD, Greenberg BH, eds. Congestive heart failure. New York: Springer-Verlag, 1994; 687-700
58. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of dilated cardiomyopathy. Am J Cardiol 1981; 47:525-31
59. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72:1059-63
60. Evans RW. Socioeconomic aspects of heart transplantation. Curr Opin Cardiol 1995; 10:169-79